Clinical calculator summary
AJCC 8th Edition Breast Cancer Stage
Clinical calculator summary
AJCC 8th Edition Breast Cancer Stage
A breast cancer staging scaffold that combines anatomic TNM with grade and receptor context.
Evidence-based context for fast calculator use
- Purpose:
- Support consistent initial breast cancer stage grouping and selection of downstream prognosis tools
- Population:
- Patients undergoing initial staging for in situ or invasive breast cancer
- Factors:
- Tumor category, Nodal category, Distant metastasis, Grade, ER status, HER2 status
- Reference:
- AJCC Cancer Staging Manual, 8th edition
AJCC Prognostic Stage (Breast)
Clinical Context & Background
Anatomic Stage = T + N + M. Prognostic Stage modifies this based on biomarkers.Reference Data
| Anatomic Stage | TNM Criteria |
|---|---|
| Stage 0 | Tis N0 M0 |
| Stage IA | T1 N0 M0 |
| Stage IB | T0/1 N1mi M0 |
| Stage IIA | T0/1 N1 M0 or T2 N0 M0 |
| Stage IIB | T2 N1 M0 or T3 N0 M0 |
| Stage IIIA | T0-2 N2 M0 or T3 N1-2 M0 |
| Stage IIIB | T4 N0-2 M0 |
| Stage IIIC | Any T N3 M0 |
| Stage IV | Any T Any N M1 |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use at initial breast cancer diagnosis to organize anatomic TNM stage together with grade and receptor context.
- Most useful before definitive treatment planning, tumor board discussion, prognosis counseling, and selection of related breast decision tools.
- Use the result as a staging scaffold, then layer treatment-specific tools such as PREDICT, Oncotype DX, RCB, or CTS5 when clinically appropriate.
How To Interpret
- The calculator returns an anatomic stage group and displays ER/HER2 biology to remind users that AJCC 8th edition prognostic stage can differ from anatomic stage.
- Earlier anatomic stages generally reflect smaller tumor burden and/or limited nodal disease; stage III/IV results need urgent multidisciplinary context.
- Biomarker-positive or biomarker-negative disease can change prognosis and treatment options even when anatomic stage is the same.
What To Do Next
- Confirm TNM, grade, ER, PR, HER2, and specimen timing in the pathology and imaging record.
- For early invasive disease after surgery, use PREDICT and selected genomic tools to support adjuvant therapy discussion.
- After neoadjuvant therapy, use post-treatment pathology and Residual Cancer Burden rather than treating this baseline staging calculator as a response tool.
Limitations
- This simplified tool does not replace the full AJCC manual, institutional staging policy, or registry-grade documentation.
- Do not use as the only staging authority after neoadjuvant therapy, recurrence, bilateral primaries, or unusual breast malignancies.
- PR status and additional prognostic modifiers must be reviewed in the source pathology record and guideline context.
Validated Population
Patients undergoing initial breast cancer staging with TNM, grade, ER, HER2, and related biomarker information available.
Example use
A T2N1M0 invasive cancer is anatomically stage IIB in this calculator. If it is ER-positive and HER2-negative, the next practical step is often adjuvant prognosis and chemotherapy-benefit assessment with tools such as PREDICT and selected genomic assays.
Related Tools
Frequently Asked Questions
Why can anatomic and prognostic breast stage differ?
AJCC prognostic stage incorporates grade and tumor biology in addition to TNM, so cancers with the same anatomic burden can have different prognostic stages.
Can this simplified calculator replace the AJCC manual?
No. Confirm unusual presentations, post-neoadjuvant staging, multifocal disease, and registry-grade documentation against the full AJCC system and institutional policy.
Evidence-based oncology decision support. Verify with clinical guidelines.